Fibromyalgia & Chronic Fatigue stem cell therapy — your questions answered (2026)

About stem cell therapy for Fibromyalgia & Chronic Fatigue

Fibromyalgia is a chronic condition characterised by widespread pain, fatigue, sleep disturbance and often cognitive symptoms. Its biology is complex and cannot be reduced to a single neurotransmitter or inflammatory pathway. Mesenchymal stromal cells (MSCs) and extracellular vesicles are being explored for proposed immunomodulatory or neuromodulatory effects, but these mechanisms have not established clinical benefit. Cell or exosome infusion is not standard fibromyalgia care. The registry table on this page lists relevant studies and their current recruitment status.

The evidence for Fibromyalgia & Chronic Fatigue

Evidence for fibromyalgia cell therapy is extremely limited and does not establish efficacy. Small uncontrolled observations cannot separate treatment effects from symptom fluctuation, placebo or concurrent care, and exploratory biomarker changes do not prove pain or functional benefit. No pooled response rate is published here because the evidence is too sparse and heterogeneous for a single figure to be meaningful. The registered studies and their own prespecified endpoints are listed in the registry table on this page.

Private investigational fibromyalgia cell or exosome procedures can involve separate charges for assessment, laboratory testing, monitoring, repeat administration and travel. Prices do not indicate regulatory approval or expected benefit. Patients should request an itemised written quote and verify sponsor, insurer and patient responsibilities. Evidence-based multimodal fibromyalgia care must not be delayed.

Can stem cells help fibromyalgia?

Cell therapy for Fibromyalgia & Chronic Fatigue may be offered as an individualised programme, but regulatory status depends on the product, processing, indication and jurisdiction. It is currently investigational. Verify authorisation status, cell source, release testing and clinical evidence for the specific proposal.

Which symptoms respond?

Schedules vary by the exact product, protocol, route, monitoring needs and clinical context. Request the proposed schedule and its evidence before making travel arrangements.

How is it delivered?

Eligibility depends on the protocol's inclusion and exclusion criteria and an appropriately qualified clinician's assessment. An online checklist cannot determine candidacy or replace medical advice.

EU cost?

The partner-published indicative range for an Fibromyalgia & Chronic Fatigue programme is €3,000–€8,000 for treatment. Request a current written quotation and compare product, dose, visits, inclusions and follow-up before using country ranges as a benchmark.

Sources & further reading

We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.

• Open clinical trials for Fibromyalgia & Chronic Fatigue (ClinicalTrials.gov) ↗
• Peer-reviewed research on PubMed ↗
• ISSCR patient guide — what to ask ↗
• FDA consumer warning on stem-cell therapies ↗
• EMA — advanced-therapy (ATMP) framework ↗

← Back to Fibromyalgia & Chronic Fatigue overview · Fibromyalgia & Chronic Fatigue cost →